Please sign in to follow a disease.
MSD R&D (China) Co., Ltd.
Clinical trials sponsored by MSD R&D (China) Co., Ltd., explained in plain language.
Research and development subsidiary of Merck & Co., a global pharmaceutical company.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
New hope for Tough-to-Treat blood cancer: MK-1045 enters human trials
Disease control Recruiting nowThis study tests a new drug called MK-1045 (CN201) in people with a type of blood cancer (B-cell acute lymphoblastic leukemia) that has come back or stopped responding to treatment. The trial has two parts: first, finding a safe dose, and then checking how well the drug works. Ab…
Phase 1/2 • Sponsor: MSD R&D (China) Co., Ltd. • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
New immunotherapy MK-1045 enters first human trial for Hard-to-Treat lymphoma
Disease control Recruiting nowThis early-stage trial is testing a new drug called MK-1045 (CN201) in about 100 people whose B-cell non-Hodgkin lymphoma has returned or stopped responding to treatment. MK-1045 is an immunotherapy designed to help the immune system fight the cancer. The main goals are to check …
Phase 1 • Sponsor: MSD R&D (China) Co., Ltd. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC